Navigation Links
Dipexium Pharmaceuticals Updates Locilex™ Development Activities and Announces 2011 Milestones
Date:4/4/2011

NEW YORK, April 4, 2011 /PRNewswire/ -- Dipexium Pharmaceuticals today provided an update of its development activities and announced its milestones to be achieved during 2011. Management announced that it has completed successfully initial six-months' stability testing on the original formulation of Locilex™ (pexiganan acetate 1% cream) and has moved on with its manufacturers to expand the batch size for clinical and commercial production.  In addition, the Company has received formal and clear clinical guidance from the FDA to support its Phase 3 clinical and regulatory pathway to resubmission of its new drug application (NDA) for Locilex™ in the U.S.

The Company also announced that its critical milestones for 2011 include the following:

  • Manufacturing:  The Company anticipates completing the work required to support its chemistry, manufacturing and controls (CMC) meeting with FDA in May 2011;
  • CMC Meeting:  The Company anticipates convening a CMC meeting with FDA in August 2011 to finalize the Company's manufacturing plans and use of product supply in the upcoming Phase 3 program;
  • Special Protocol Assessment (SPA) Filing:  The Company intends to file for a SPA designation in September 2011 shortly after the tentatively planned scheduled CMC meeting.

"Successfully achieving these value-inflection points should significantly reduce the risk associated with completing the drug development of Locilex™ and position the Company for further financing or other strategic alternatives," stated David P. Luci, Co-Founder & Managing Partner.

About Dipexium:

Dipexium Pharmaceuticals, LLC is an emerging biopharmaceutical company initially formed to complete the development and initiate the commercialization of Locilex™ (pexiganan acetate 1% cream), a novel, small peptide anti-infective agent. Locilex™ is formulated
'/>"/>

SOURCE Dipexium Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
2. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
3. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
4. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
5. Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
6. Reportlinker Adds Top 500 Pharmaceuticals Industry Report (Global)
7. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
8. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
9. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... ANA598 demonstrates favorable preclinical antiviral, metabolic, ... preliminary toxicologic properties, SAN DIEGO, Sept. 11 ... preclinical data today on ANA598, a,non-nucleoside inhibitor of ... the 14th International Symposium on Hepatitis C Virus ...
... have or have,ever had chronic heartburn, you may be ... severe gastroesophageal reflux disease,(GERD). Barrett,s esophagus has been recognized ... esophagus, the seventh deadliest cancer in men in,the United ... in the lining of the,esophagus, which can progress to ...
Cached Medicine Technology:Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer 2
(Date:4/24/2014)... of Manchester have identified a way to sensitise cancer ... treatment. , The study published today in Cell ... of drugs to target cells that have become resistant ... whilst exploring the possible mechanisms behind resistance to chemotherapy ... colon cancer. , Dr Andrew Gilmore, who led the ...
(Date:4/24/2014)... 2014 Scientific research at UT Southwestern Medical Center ... itself completely, whereas the adult heart lacks this ability. ... why the heart loses its incredible regenerative capability in ... , Yes, oxygen. It is well-known that a ... blood throughout the body. But at the same time, ...
(Date:4/24/2014)... coated with an antimicrobial peptide could help to lower the ... Optometry and Vision Science , official journal of ... is published by Lippincott Williams & Wilkins , a ... animals and now humans support the biocompatibility and safety of ... new research by Debarun Dutta, B.Optom, of The University of ...
(Date:4/24/2014)... DURHAM, N.C. Changes in managing patients before, during ... days and reduced readmission rates, according to researchers who ... Hospital. , The practice, called enhanced recovery, is easier ... period and bowel evacuation that are typically prescribed. After ... as soon as possible, leading to faster recoveries. , ...
(Date:4/24/2014)... the new Institute for Biomedical Sciences at Georgia ... federal grant to develop novel therapeutics against Respiratory ... the Eunice Kennedy Shriver National Institute Of Child ... of Health will support Plemper,s drug development goals ... one distinct alternative compound. , Infections by RSV, ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Oxygen diminishes the heart's ability to regenerate, researchers discover 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3
... thousands of elderly people in England have come under ... for Social Care Inspection many elderly people found their ... trust. ,The practice of giving 15 minute ... individual, was accused fo being "undignified and unsafe". The ...
... An HIV/AIDS vaccine has proved to be efficient on animals according ... ,"Perhaps we can cure HIV infection. This is our hope," said ... of the vaccine are expected soon with almost $5i million to ... this new medical revelation. ,Dr. Yong Kang said, ...
... have conducted a randomised, placebo controlled, double blind trial on ... the popular antiaging// supplement DHEA(dehydroepiandrosterone). The report published in the ... with the findings that DHEA cannot be considered the magic ... that the drug does not have any marked impact on ...
... effects of the country's worst epidemic of the mosquito-borne ... been infected by Chikungunya,// according to the World Health ... by the WHO, over 1.25 million suspected cases have ... is debilitating with severe joint pain and high fever. ...
... A new experimental vaccine developed by scientists in the US ... help prevent the disease that has kills one million// people ... S and developed by Walter Reed Army Institute of Research ... percent for up to 18 months after vaccination among children ...
... Hopkins have shown that transplanting human stem cells into ... disease delays the start of nerve// cell damage typical ... stem cells develop into nerve cells that make substantial ... to Lou Gehrig’s, also known as amyotrophic lateral sclerosis ...
Cached Medicine News:Health News:Standards of Home Care for Elderly Needs Change 2Health News:The Search For Eternal Youth-DHEA Not The Magic Potion 2Health News:45% of Indians Affected by Chikungunya Fever 2Health News:Human Stem Cells Delay Start of Lou Gehrig’s Disease in Rat 2Health News:Human Stem Cells Delay Start of Lou Gehrig’s Disease in Rat 3
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
... The Sysmex CA-7000 provides speed ... that is synonymous with Sysmex technology. ... CA-7000 offers throughput of up to ... hour in multi-parameter testing. This ...
... The Sysmex CA-1500 enhances productivity in the ... utilizes three detection methods clotting, chromogenic ... accurate and precise test results every time. ... communication options and random access, the CA-1500 ...
... is the lancing device that has set ... since 1983. This re-usable lancing device assists ... The auto-Lancet is constructed in the USA ... after day, year after year. It's the ...
Medicine Products: